Introduction The green biotech industry in South Korea, which transforms local agricultural products into high value health foods and cosmetics, is
Category: Licensing Deals
FDA Greenlights Ezplaz: A Revolutionary Step in Emergency Plasma Transfusions
In a significant advancement for emergency medicine, the Food and Drug Administration (FDA) has granted approval for Ezplaz Freeze Dried Plasma, the first
Understanding Arterra Bioscience and Its Market Position
Arterra Bioscience SpA represents a notable entity in the biotech landscape, particularly through its ordinary shares (ARBS). The firm is gaining
법률신문
법률 전문가의 경로와 비법 전문 지식과 배경 변호사 곽재우는 서울대학교 산업공학과를 졸업한 후 지식재산권(IP) 분야의 전문가로 자리매김했습니다. 그의 학업 성적은 최우수 졸업생으로서의 자격을 증명하며, 공학 배경은 그가 법률 문제를 접근하는 데 있어 독특한 시각을
The Rising Epidemic of Erectile Dysfunction Among Young Men
Young men in America are increasingly facing a daunting challenge in their intimate lives. A rising number of males in their sexual prime are grappling
The Rise of Chinese Biopharma: Major Deals Transforming the Industry
In the past 16 months, Chinese biotechnology companies have emerged as significant players in the global pharmaceutical landscape. They have participated
The Transformation of Mental Health Care Access Through Telehealth
Telehealth is revolutionizing the landscape of mental health care in the United States by breaking down traditional barriers such as location, cost, and
China’s Biopharmaceutical Sector: A New Era of Innovation
China’s biopharmaceutical landscape is experiencing a remarkable transformation as it kicks off 2026 with unprecedented growth in cross border out
Yahoo Finance
جانکس تھراپیٹکس نے بی ایم وائی معاہدے سے 35 ملین ڈالر کی سنگ میل کی ادائیگی حاصل کی جانکس تھراپیٹکس (JANX) نے بایوٹیک کمپنی برسٹول مائرز اسکوئب (BMY) کے
Insmed: Aligning Pipeline Potential with Market Valuation
Insmed has been making waves in the pulmonary arterial hypertension (PAH) landscape. The company, known for its innovative treatments, is gradually
Enhancing Resilience: Neurofeedback Therapy at the Presidio of Monterey
The Presidio of Monterey is taking a significant step forward in supporting its military community by incorporating neurofeedback therapy into its
A New Chapter for Novo Nordisk: The Impact of Wegovy’s High-Dose Approval
Novo Nordisk, a powerhouse in the pharmaceutical industry, faces a pivotal moment as it seeks to reclaim its dominance in the weight loss market. Once
Johnson & Johnson and Royalty Pharma Forge $500 Million Partnership for Autoimmune Treatment
Johnson & Johnson (JNJ) has secured a significant partnership with Royalty Pharma, aimed at advancing research in autoimmune diseases. This collaboration,
Theravance Biopharma’s Strategic Settlement on YUPELRI Patent Litigation
Theravance Biopharma has made significant strides in its legal and commercial landscape with a recent settlement concerning YUPELRI, its inhalation
Understanding Material Breach Clauses in Licensing Agreements
Material breach clauses play a critical role in licensing agreements, governing the rights and responsibilities of the parties involved. These clauses
Ligand Pharmaceuticals: An Insider Sale Amidst Significant Growth
Ligand Pharmaceuticals, a dynamic player in the biotech arena, has recently come under the spotlight due to a notable insider transaction. The Chief
Ligand Pharmaceuticals: Insider Sale Signals Confidence Amid Growth
Ligand Pharmaceuticals has recently garnered attention following an insider transaction that underscores the company’s robust performance and strategic
Evaluating Johnson & Johnson: Is the Stock Still a Bargain?
Johnson & Johnson (NYSE: JNJ) has long been a cornerstone of the pharmaceutical industry, celebrated for its vast diversification and resilience. With a
Antengene and UCB Forge Strategic Alliance for Innovative Autoimmune Treatment
Antengene Corporation Limited has announced a significant global licensing agreement with UCB for its bispecific T cell engager (TCE), ATG 201, aimed at
Strategic Partnership: Antengene and UCB Collaborate on ATG-201 for Autoimmune Treatment
Antengene and UCB have forged a significant global license agreement focusing on ATG 201, a bispecific T cell engager targeting CD19 and CD3. This
Tenaya Therapeutics Soars Following Strategic Collaboration with Alnylam Pharmaceuticals
Tenaya Therapeutics has captured market attention with a significant surge in its stock price, following the announcement of a research collaboration